[ad_1]
SAN CARLOS, Calif., March 01, 2024 (GLOBE NEWSWIRE) — Iovance Biotherapeutics, Inc. (Nasdaq: IOVA) is a biotechnology company focused on innovating, developing and delivering novel polyclonals to cancer patients Tumor-infiltrating lymphocyte (TIL) therapy. Cancer, today announced senior leadership plans to attend the following meetings:
-
TD Cowen 44th Annual Healthcare Conference
Fireside Chat: March 4, 2024, 11:10 a.m. ET
Boston, Massachusetts
-
Barclays 26th Annual Global Healthcare Conference
Fireside Chat: March 12, 2024 at 10:45 a.m. ET
Miami, Florida
Live and archived webcasts will be available at https://ir.iovance.com/news-events/events-presentations.
About Iovance Biotherapeutics
Iovance Biotherapeutics, Inc. aims to be a global leader in innovating, developing and delivering tumor-infiltrating lymphocyte (TIL) therapies to patients with cancer. We are pioneering a transformative approach to treating cancer that harnesses the body’s immune system’s ability to recognize and destroy different cancer cells in each patient’s body. The Iovance TIL platform has demonstrated promising clinical data in a variety of solid tumors. Iovance’s Amtagvi™ is the first FDA-approved T-cell therapy for a solid tumor indication. We are committed to continued innovation in cell therapies, including gene-edited cell therapies, that may extend and improve the lives of cancer patients. For more information, please visit www.iovance.com.
Amtagvi™ and its accompanying design trademark Proleukin®John Vance®, and IovanceCares™ are trademarks and registered trademarks of Iovance Biotherapeutics, Inc. or its subsidiaries. All other trademarks and registered trademarks are the property of their respective owners.
forward-looking statements
Certain matters discussed in this press release are “forward-looking statements” within the meaning of the private securities of Iovance Biotherapeutics, Inc. (the “Company,” “we,” or “our”) under the Litigation Reform Act of 1995 (“PSLRA” ). Without limiting the foregoing, in some cases we may use the terms “forecast,” “believe,” “potential,” “continue,” “estimate,” “anticipate,” “expect,” “plan” , terms such as “intend”, “forecast”, “guidance”, “outlook”, “may”, “could”, “could”, “will”, “should” or other words expressing uncertainty about future events or results Words intended to identify forward-looking statements. Forward-looking statements are based on assumptions and assessments based on management’s experience and perception of historical trends, current conditions, expected future developments and other factors deemed appropriate. The forward-looking statements in this press release are made as of the date of this press release, and we undertake no obligation to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors, many of which are beyond our control, that could cause actual results, levels of activity, performance, achievements and development to be materially affected. differ from those expressed or implied in these forward-looking statements. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the section titled “Risk Factors” in our filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and quarterly reports on Form 10-Q, including, but not limited to, the following material known and unknown risks and uncertainties inherent in our business: risks related to our ability to successfully commercialize our products, including Amtagvi and Proleukin, We have received approval from the U.S. Food and Drug Administration (“FDA”), the European Medicines Agency (“EMA”) or other regulatory authorities; the EMA or other regulatory authorities may not approve or may delay approval of our submission for the treatment of metastatic melanoma risks to the biologics license application (“BLA”) for lifileucel in oncology; market acceptance of our products, including Amtagvi and Proleukin, in the U.S. and other international markets, and potential pricing and/or reimbursement by payers, if approved (with respect to our product candidates), and whether such acceptance will be sufficient to support the continued commercialization or development of our products, including Amtagvi and Proleukin or product candidates; whether we will be able to use third-party manufacturers or in our own Facilities manufacturing our therapies could adversely affect our commercial launch; results from clinical trials conducted with collaborators using different manufacturing processes may not be reflected in our sponsored trials; risks associated with the recent successful integration of the Proleukin acquisition; our The successful development or commercialization of our products, including Amtagvi and Proleukin, may not generate sufficient revenue from product sales, and we may not be profitable in the short term or at all; future competition or other market factors may have adverse effects on the business of Amtagvi or Proleukin. risks related to the potential for adverse effects on our product candidates; risks related to the timing and ability to successfully develop, submit, obtain or maintain approval or other action by the FDA, EMA or other regulatory authorities for our product candidates; risks associated with our pivotal studies and cohorts Whether clinical trial results and meetings with the FDA, EMA or other regulatory authorities can support registration studies and subsequent approval by the FDA, EMA or other regulatory authorities, including the risk of the planned single-arm phase 2 IOV-LUN-202 trial version may not support Registration; preliminary and interim clinical results (which may include efficacy and safety results) from ongoing clinical trials or cohorts may not be reflected in final results from our ongoing clinical trials or subgroups from these trials or other prior trials or cohorts. Under analysis; Risks for enrollment in our trials and cohorts in these trials may need to be adjusted based on input from the FDA and other regulatory authorities; Risks that changes in the care environment for patients with cervical cancer may impact our clinical trials in this indication ; The risk that we may need to conduct additional clinical trials or modify ongoing or future clinical trials based on feedback from the FDA, EMA or other regulatory authorities; Our interpretation of clinical trial results or communications with the FDA, EMA or other regulatory authorities may Unlike the interpretation of such results or communications by such regulatory authorities (including our prior discussions with the FDA regarding our non-small cell lung cancer clinical trials); clinical data from ongoing Amtagvi clinical trials are not ongoing or planned. the risk that our clinical trials will be repeated, or that regulatory approvals or authorization updates may not be supported; the risk that unexpected expenses may reduce our estimated cash balances and forecasts and increase our estimated capital requirements; the impact of the COVID-19 pandemic; and Other factors, including general economic conditions and regulatory developments, are beyond our control.
contact method
Iovance Biotherapeutics:
Sara Pellegrino, IRC
Senior Vice President, Investor Relations and Corporate Communications
650-260-7120 extension 264
Sara.Pellegrino@iovance.com
Jane Sanders
Senior Director, Investor Relations and Corporate Communications
267-485-3119
Jen.Saunders@iovance.com
[ad_2]
Source link